Troluce Capital Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Troluce Capital Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-99,600	Closed	-$22.8M	–	35
2026 Q1	$22.8M	Buy	+99,600	New	+$22.3M	1.4%	24
2025 Q4	–	Sell	-30,000	Closed	-$5.96M	–	16
2025 Q3	$5.96M	Hold	30,000	–	–	0.83%	26
2025 Q2	$5.18M	Buy	+30,000	New	+$4.89M	1.23%	18

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Troluce Capital Advisors's ASND Position: Q2 2026 in Review

Troluce Capital Advisors sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 99,600 shares — an estimated $22.8M sold.

Troluce Capital Advisors first reported a position in ASND in Q2 2025 and held it in 3 quarters. The position peaked at $22.8M in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Troluce Capital Advisors reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Troluce Capital Advisors sold 99,600 Ascendis Pharma A/S shares in Q2 2026, an estimated $22.8M.
Troluce Capital Advisors first reported a position in Ascendis Pharma A/S in Q2 2025 and held it in 3 quarters.
Troluce Capital Advisors's Ascendis Pharma A/S position peaked at $22.8M in Q1 2026.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Troluce Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.